Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Clinical Pharmacokinetics
Erschienen in: Clinical Pharmacokinetics 9/2018

06.03.2018 | Review Article

Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Inflammatory Bowel Disease

verfasst von: Luc J. J. Derijks, Dennis R. Wong, Daniel W. Hommes, Adriaan A. van Bodegraven

Erschienen in: Clinical Pharmacokinetics | Ausgabe 9/2018

Einloggen, um Zugang zu erhalten

Abstract

According to recent clinical consensus, pharmacotherapy of inflammatory bowel disease (IBD) is, or should be, personalized medicine. IBD treatment is complex, with highly different treatment classes and relatively few data on treatment strategy. Although thorough evidence-based international IBD guidelines currently exist, appropriate drug and dose choice remains challenging as many disease (disease type, location of disease, disease activity and course, extraintestinal manifestations, complications) and patient characteristics [(pharmaco-)genetic predisposition, response to previous medications, side-effect profile, necessary onset of response, convenience, concurrent therapy, adherence to (maintenance) therapy] are involved. Detailed pharmacological knowledge of the IBD drug arsenal is essential for choosing the right drug, in the right dose, in the right administration form, at the right time, for each individual patient. In this in-depth review, clinical pharmacodynamic and pharmacokinetic considerations are provided for tailoring treatment with the most common IBD drugs. Development (with consequent prospective validation) of easy-to-use treatment algorithms based on these considerations and new pharmacological data may facilitate optimal and effective IBD treatment, preferably corroborated by effectiveness and safety registries.
Literatur
1.
2.
3.
4.
Gomollon F, Dignass A, Annese V, et al. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 1: Diagnosis and Medical Management. J Crohns Colitis. 2017;11(1):3–25.PubMedCrossRef
5.
Dignass A, Lindsay JO, Sturm A, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis. 2012;6(10):991–1030.PubMedCrossRef
6.
Baert F, Caprilli R, Angelucci E. Medical therapy for Crohn’s disease: top-down or step-up? Dig Dis. 2007;25(3):260–6.PubMedCrossRef
7.
Present DH. How to do without steroids in inflammatory bowel disease. Inflamm Bowel Dis. 2000;6(1):48–57 (discussion 58.).PubMedCrossRef
8.
Peyrin-Biroulet L, Lemann M. Review article: remission rates achievable by current therapies for inflammatory bowel disease. Aliment Pharmacol Ther. 2011;33(8):870–9.PubMedCrossRef
9.
Turner D, Walsh CM, Steinhart AH, et al. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol. 2007;5(1):103–10.PubMedCrossRef
10.
Quetglas EG, Armuzzi A, Wigge S, et al. Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment. Eur J Clin Pharmacol. 2015;71(7):773–99.PubMedCrossRef
11.
Ardizzone S, Maconi G, Russo A, et al. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut. 2006;55(1):47–53.PubMedPubMedCentralCrossRef
12.
Rang HP, Dale MM, Ritter JM. Pharmacology. 3rd ed. Edinburgh: Churchill Livingstone; 1996.
13.
Thiesen A, Thomson AB. Review article: older systemic and newer topical glucocorticosteroids and the gastrointestinal tract. Aliment Pharmacol Ther. 1996;10(4):487–96.PubMedCrossRef
14.
Neal MJ. Medical Pharmacology at a Glance. 3rd ed. Oxford: Blackwell Science Ltd; 1997.
15.
Schwab M, Klotz U. Pharmacokinetic considerations in the treatment of inflammatory bowel disease. Clin Pharmacokinet. 2001;40(10):723–51.PubMedCrossRef
16.
Hanauer SB. Advantages in IBD: Current Developments in the Treatment of Inflammatory Bowel Diseases. Gastroenterol Hepatol (N Y). 2010;6(5):309–16.
17.
18.
van Bodegraven AA, van Everdingen JJ, Dijkstra G, et al. Guideline ‘Diagnosis and treatment of inflammatory bowel disease in adults. I. Diagnosis and treatment. Ned Tijdschr Geneeskd. 2010;154:A1899.PubMed
19.
Frey BM, Frey FJ. Clinical pharmacokinetics of prednisone and prednisolone. Clin Pharmacokinet. 1990;19(2):126–46.PubMedCrossRef
20.
Tanner A, Bochner F, Caffin J, et al. Dose-dependent prednisolone kinetics. Clin Pharmacol Ther. 1979;25(5 Pt 1):571–8.PubMedCrossRef
21.
Bergrem H, Grottum P, Rugstad HE. Pharmacokinetics and protein binding of prednisolone after oral and intravenous administration. Eur J Clin Pharmacol. 1983;24(3):415–9.PubMedCrossRef
22.
Rose JQ, Yurchak AM, Jusko WJ. Dose dependent pharmacokinetics of prednisone and prednisolone in man. J Pharmacokinet Biopharm. 1981;9(4):389–417.PubMedCrossRef
23.
Wald JA, Law RM, Ludwig EA, et al. Evaluation of dose-related pharmacokinetics and pharmacodynamics of prednisolone in man. J Pharmacokinet Biopharm. 1992;20(6):567–89.PubMedCrossRef
24.
Pickup ME. Clinical pharmacokinetics of prednisone and prednisolone. Clin Pharmacokinet. 1979;4(2):111–28.PubMedCrossRef
25.
Davis M, Williams R, Chakraborty J, et al. Prednisone or prednisolone for the treatment of chronic active hepatitis? A comparison of plasma availability. Br J Clin Pharmacol. 1978;5(6):501–5.PubMedPubMedCentralCrossRef
26.
Olivesi A. Modified elimination of prednisolone in epileptic patients on carbamazepine monotherapy, and in women using low-dose oral contraceptives. Biomed Pharmacother. 1986;40(8):301–8.PubMed
27.
Bartoszek M, Brenner AM, Szefler SJ. Prednisolone and methylprednisolone kinetics in children receiving anticonvulsant therapy. Clin Pharmacol Ther. 1987;42(4):424–32.PubMedCrossRef
28.
Legler UF. Impairment of prednisolone disposition in patients with Graves’ disease taking methimazole. J Clin Endocrinol Metab. 1988;66(1):221–3.PubMedCrossRef
29.
Legler UF. Enhanced prednisolone elimination: a possible cause for failure of glucocorticoid therapy in Graves’ ophthalmopathy. Horm Metab Res. 1987;19(4):168–70.PubMedCrossRef
30.
Meffin PJ, Wing LM, Sallustio BC, et al. Alterations in prednisolone disposition as a result of oral contraceptive use and dose. Br J Clin Pharmacol. 1984;17(6):655–64.PubMedPubMedCentralCrossRef
31.
Legler UF, Benet LZ. Marked alterations in dose-dependent prednisolone kinetics in women taking oral contraceptives. Clin Pharmacol Ther. 1986;39(4):425–9.PubMedCrossRef
32.
Derendorf H, Mollmann H, Rohdewald P, et al. Kinetics of methylprednisolone and its hemisuccinate ester. Clin Pharmacol Ther. 1985;37(5):502–7.PubMedCrossRef
33.
Mollmann H, Rohdewald P, Barth J, et al. Comparative pharmacokinetics of methylprednisolone phosphate and hemisuccinate in high doses. Pharm Res. 1988;5(8):509–13.PubMedCrossRef
34.
Mollmann H, Rohdewald P, Barth J, et al. Pharmacokinetics and dose linearity testing of methylprednisolone phosphate. Biopharm Drug Dispos. 1989;10(5):453–64.PubMedCrossRef
35.
36.
Ludwig EA, Kong AN, Camara DS, et al. Pharmacokinetics of methylprednisolone hemisuccinate and methylprednisolone in chronic liver disease. J Clin Pharmacol. 1993;33(9):805–10.PubMedCrossRef
37.
Fost DA, Leung DY, Martin RJ, et al. Inhibition of methylprednisolone elimination in the presence of clarithromycin therapy. J Allergy Clin Immunol. 1999;103(6):1031–5.PubMedCrossRef
38.
Glynn AM, Slaughter RL, Brass C, et al. Effects of ketoconazole on methylprednisolone pharmacokinetics and cortisol secretion. Clin Pharmacol Ther. 1986;39(6):654–9.PubMedCrossRef
39.
Varis T, Kaukonen KM, Kivisto KT, et al. Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole. Clin Pharmacol Ther. 1998;64(4):363–8.PubMedCrossRef
40.
Varis T, Kivisto KT, Neuvonen PJ. Grapefruit juice can increase the plasma concentrations of oral methylprednisolone. Eur J Clin Pharmacol. 2000;56(6–7):489–93.PubMedCrossRef
41.
Varis T, Kivisto KT, Neuvonen PJ. The effect of itraconazole on the pharmacokinetics and pharmacodynamics of oral prednisolone. Eur J Clin Pharmacol. 2000;56(1):57–60.PubMedCrossRef
42.
Kandrotas RJ, Slaughter RL, Brass C, et al. Ketoconazole effects on methylprednisolone disposition and their joint suppression of endogenous cortisol. Clin Pharmacol Ther. 1987;42(4):465–70.PubMedCrossRef
43.
Slayter KL, Ludwig EA, Lew KH, et al. Oral contraceptive effects on methylprednisolone pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 1996;59(3):312–21.PubMedCrossRef
44.
Toothaker RD, Welling PG. Effect of dose size on the pharmacokinetics of intravenous hydrocortisone during endogenous hydrocortisone suppression. J Pharmacokinet Biopharm. 1982;10(2):147–56.PubMedCrossRef
45.
Hamedani R, Feldman RD, Feagan BG. Review article: Drug development in inflammatory bowel disease: budesonide – a model of targeted therapy. Aliment Pharmacol Ther. 1997;11(Suppl 3):98–107 (discussion 107–8).PubMed
46.
Hoy SM. Budesonide MMX((R)): a review of its use in patients with mild to moderate ulcerative colitis. Drugs. 2015;75(8):879–86.PubMedCrossRef
47.
Ryrfeldt A, Edsbacker S, Pauwels R. Kinetics of the epimeric glucocorticoid budesonide. Clin Pharmacol Ther. 1984;35(4):525–30.PubMedCrossRef
48.
Spencer CM, McTavish D. Budesonide. A review of its pharmacological properties and therapeutic efficacy in inflammatory bowel disease. Drugs. 1995;50(5):854–72.PubMedCrossRef
49.
D’Haens G. Systematic review: second-generation vs. conventional corticosteroids for induction of remission in ulcerative colitis. Aliment Pharmacol Ther. 2016;44(10):1018–29.PubMedCrossRef
50.
Edsbacker S, Andersson T. Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn’s disease. Clin Pharmacokinet. 2004;43(12):803–21.PubMedCrossRef
51.
Seidegard J. Reduction of the inhibitory effect of ketoconazole on budesonide pharmacokinetics by separation of their time of administration. Clin Pharmacol Ther. 2000;68(1):13–7.PubMedCrossRef
52.
Gross V, Bar-Meir S, Lavy A, et al. Budesonide foam versus budesonide enema in active ulcerative proctitis and proctosigmoiditis. Aliment Pharmacol Ther. 2006;23(2):303–12.PubMedCrossRef
53.
Brunner M, Vogelsang H, Greinwald R, et al. Colonic spread and serum pharmacokinetics of budesonide foam in patients with mildly to moderately active ulcerative colitis. Aliment Pharmacol Ther. 2005;22(5):463–70.PubMedCrossRef
54.
Rubin DT, Sandborn WJ, Bosworth B, et al. Budesonide foam has a favorable safety profile for inducing remission in mild-to-moderate ulcerative proctitis or proctosigmoiditis. Dig Dis Sci. 2015;60(11):3408–17.PubMedPubMedCentralCrossRef
55.
Bergman R, Parkes M. Systematic review: the use of mesalazine in inflammatory bowel disease. Aliment Pharmacol Ther. 2006;23(7):841–55.PubMedCrossRef
56.
Azad Khan AK, Piris J, Truelove SC. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet. 1977;2(8044):892–5.PubMedCrossRef
57.
Frieri G, Giacomelli R, Pimpo M, et al. Mucosal 5-aminosalicylic acid concentration inversely correlates with severity of colonic inflammation in patients with ulcerative colitis. Gut. 2000;47(3):410–4.PubMedPubMedCentralCrossRef
58.
Naganuma M, Iwao Y, Ogata H, et al. Measurement of colonic mucosal concentrations of 5-aminosalicylic acid is useful for estimating its therapeutic efficacy in distal ulcerative colitis: comparison of orally administered mesalamine and sulfasalazine. Inflamm Bowel Dis. 2001;7(3):221–5.PubMedCrossRef
59.
Rousseaux C, Lefebvre B, Dubuquoy L, et al. Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma. J Exp Med. 2005;201(8):1205–15.PubMedPubMedCentralCrossRef
60.
61.
Mahida YR, Lamming CE, Gallagher A, et al. 5-Aminosalicylic acid is a potent inhibitor of interleukin 1 beta production in organ culture of colonic biopsy specimens from patients with inflammatory bowel disease. Gut. 1991;32(1):50–4.PubMedPubMedCentralCrossRef
62.
Rachmilewitz D, Karmeli F, Schwartz LW, et al. Effect of aminophenols (5-ASA and 4-ASA) on colonic interleukin-1 generation. Gut. 1992;33(7):929–32.PubMedPubMedCentralCrossRef
63.
Kaiser GC, Yan F, Polk DB. Mesalamine blocks tumor necrosis factor growth inhibition and nuclear factor kappaB activation in mouse colonocytes. Gastroenterology. 1999;116(3):602–9.PubMedCrossRef
64.
Egan LJ, Mays DC, Huntoon CJ, et al. Inhibition of interleukin-1-stimulated NF-kappaB RelA/p65 phosphorylation by mesalamine is accompanied by decreased transcriptional activity. J Biol Chem. 1999;274(37):26448–53.PubMedCrossRef
65.
Sharon P, Ligumsky M, Rachmilewitz D, et al. Role of prostaglandins in ulcerative colitis. Enhanced production during active disease and inhibition by sulfasalazine. Gastroenterology. 1978;75(4):638–40.PubMed
66.
67.
Stenson WF. Role of eicosanoids as mediators of inflammation in inflammatory bowel disease. Scand J Gastroenterol Suppl. 1990;172:13–8.PubMedCrossRef
68.
Ahnfelt-Ronne I, Nielsen OH, Christensen A, et al. Clinical evidence supporting the radical scavenger mechanism of 5-aminosalicylic acid. Gastroenterology. 1990;98(5 Pt 1):1162–9.PubMedCrossRef
69.
Shanahan F, Niederlehner A, Carramanzana N, et al. Sulfasalazine inhibits the binding of TNF alpha to its receptor. Immunopharmacology. 1990;20(3):217–24.PubMedCrossRef
70.
Lyakhovich A, Gasche C. Systematic review: molecular chemoprevention of colorectal malignancy by mesalazine. Aliment Pharmacol Ther. 2010;31(2):202–9.PubMed
71.
Bonovas S, Fiorino G, Lytras T, et al. Systematic review with meta-analysis: use of 5-aminosalicylates and risk of colorectal neoplasia in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2017;45(9):1179–92.PubMedCrossRef
72.
Klotz U, Maier KE. Pharmacology and pharmacokinetics of 5-aminosalicylic acid. Dig Dis Sci. 1987;32(12 Suppl):46S–50S.PubMedCrossRef
73.
Layer PH, Goebell H, Keller J, et al. Delivery and fate of oral mesalamine microgranules within the human small intestine. Gastroenterology. 1995;108(5):1427–33.PubMedCrossRef
74.
75.
Zhou SY, Fleisher D, Pao LH, et al. Intestinal metabolism and transport of 5-aminosalicylate. Drug Metab Dispos. 1999;27(4):479–85.PubMed
76.
Liang E, Proudfoot J, Yazdanian M. Mechanisms of transport and structure-permeability relationship of sulfasalazine and its analogs in Caco-2 cell monolayers. Pharm Res. 2000;17(10):1168–74.PubMedCrossRef
77.
Yacyshyn B, Maksymowych W, Bowen-Yacyshyn MB. Differences in P-glycoprotein-170 expression and activity between Crohn’s disease and ulcerative colitis. Hum Immunol. 1999;60(8):677–87.PubMedCrossRef
78.
Rijk MC, van Schaik A, van Tongeren JH. Disposition of 5-aminosalicylic acid by 5-aminosalicylic acid-delivering compounds. Scand J Gastroenterol. 1988;23(1):107–12.PubMedCrossRef
79.
Harris MS, Lichtenstein GR. Review article: delivery and efficacy of topical 5-aminosalicylic acid (mesalazine) therapy in the treatment of ulcerative colitis. Aliment Pharmacol Ther. 2011;33(9):996–1009.PubMedCrossRef
80.
Sonu I, Lin MV, Blonski W, et al. Clinical pharmacology of 5-ASA compounds in inflammatory bowel disease. Gastroenterol Clin North Am. 2010;39(3):559–99.PubMedCrossRef
81.
Brunner M, Greinwald R, Kletter K, et al. Gastrointestinal transit and release of 5-aminosalicylic acid from 153Sm-labelled mesalazine pellets vs. tablets in male healthy volunteers. Aliment Pharmacol Ther. 2003;17(9):1163–9.PubMedCrossRef
82.
Rijk MC, van Hogezand RA, van Schaik A, et al. Disposition of 5-aminosalicylic acid from 5-aminosalicylic acid-delivering drugs during accelerated intestinal transit in healthy volunteers. Scand J Gastroenterol. 1989;24(10):1179–85.PubMedCrossRef
83.
Rijk MC, van Schaik A, van Tongeren JH. Disposition of mesalazine from mesalazine-delivering drugs in patients with inflammatory bowel disease, with and without diarrhoea. Scand J Gastroenterol. 1992;27(10):863–8.PubMedCrossRef
84.
Staerk Laursen L, Stokholm M, Bukhave K, et al. Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion. Gut. 1990;31(11):1271–6.PubMedPubMedCentralCrossRef
85.
Campieri M, Corbelli C, Gionchetti P, et al. Spread and distribution of 5-ASA colonic foam and 5-ASA enema in patients with ulcerative colitis. Dig Dis Sci. 1992;37(12):1890–7.PubMedCrossRef
86.
Schoonjans R, De Vos M, Schelfhout AM, et al. Distribution and concentrations of 5-aminosalicylic acid in rectosigmoid biopsy specimens after rectal administration. Dis Colon Rectum. 1996;39(7):788–93.PubMedCrossRef
87.
van Bodegraven AA, Boer RO, Lourens J, et al. Distribution of mesalazine enemas in active and quiescent ulcerative colitis. Aliment Pharmacol Ther. 1996;10(3):327–32.PubMedCrossRef
88.
Jacobsen BA, Abildgaard K, Rasmussen HH, et al. Availability of mesalazine (5-aminosalicylic acid) from enemas and suppositories during steady-state conditions. Scand J Gastroenterol. 1991;26(4):374–8.PubMedCrossRef
89.
Adler DJ, Korelitz BI. The therapeutic efficacy of 6-mercaptopurine in refractory ulcerative colitis. Am J Gastroenterol. 1990;85(6):717–22.PubMed
90.
Pearson DC, May GR, Fick GH, et al. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med. 1995;123(2):132–42.PubMedCrossRef
91.
Sandborn WJ. A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate. Am J Gastroenterol. 1996;91(3):423–33.PubMed
92.
Korelitz BI, Adler DJ, Mendelsohn RA, et al. Long-term experience with 6-mercaptopurine in the treatment of Crohn’s disease. Am J Gastroenterol. 1993;88(8):1198–205.PubMed
93.
Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut. 2002;50(4):485–9.PubMedPubMedCentralCrossRef
94.
Jharap B, Seinen ML, de Boer NK, et al. Thiopurine therapy in inflammatory bowel disease patients: analyses of two 8-year intercept cohorts. Inflamm Bowel Dis. 2010;16(9):1541–9.PubMedCrossRef
95.
McGovern DP, Travis SP, Duley J, et al. Azathioprine intolerance in patients with IBD may be imidazole-related and is independent of TPMT activity. Gastroenterology. 2002;122(3):838–9.PubMedCrossRef
96.
Hindorf U, Lindqvist M, Hildebrand H, et al. Adverse events leading to modification of therapy in a large cohort of patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2006;24(2):331–42.PubMedCrossRef
97.
Meijer B, Seinen ML, Leijte NN, et al. Clinical value of mercaptopurine after failing azathioprine therapy in patients with inflammatory bowel disease. Ther Drug Monit. 2016;38(4):463–70.PubMedCrossRef
98.
Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol. 1992;43(4):329–39.PubMedCrossRef
99.
Derijks LJ, Gilissen LP, Hooymans PM, et al. Review article: thiopurines in inflammatory bowel disease. Aliment Pharmacol Ther. 2006;24(5):715–29.PubMedCrossRef
100.
Cuffari C, Hunt S, Bayless TM. Enhanced bioavailability of azathioprine compared to 6-mercaptopurine therapy in inflammatory bowel disease: correlation with treatment efficacy. Aliment Pharmacol Ther. 2000;14(8):1009–14.PubMedCrossRef
101.
Broekman MMTJ, Coenen MJH, Wante n GJ, et al. Risk factors for thiopurine-induced myelosuppression and infections in inflammatory bowel disease patients with a normal TPMT genotype. Aliment Pharmacol Ther. 2017;46(10):953–63.
102.
Lennard L, Lilleyman JS. Individualizing therapy with 6-mercaptopurine and 6-thioguanine related to the thiopurine methyltransferase genetic polymorphism. Ther Drug Monit. 1996;18(4):328–34.PubMedCrossRef
103.
Van Asseldonk DP, de Boer NK, Peters GJ, et al. On therapeutic drug monitoring of thiopurines in inflammatory bowel disease; pharmacology, pharmacogenomics, drug intolerance and clinical relevance. Curr Drug Metab. 2009;10(9):981–97.PubMedCrossRef
104.
Dubinsky MC, Hassard PV, Seidman EG, et al. An open-label pilot study using thioguanine as a therapeutic alternative in Crohn’s disease patients resistant to 6-mercaptopurine therapy. Inflamm Bowel Dis. 2001;7(3):181–9.PubMedCrossRef
105.
Derijks LJ, de Jong DJ, Gilissen LP, et al. 6-Thioguanine seems promising in azathioprine- or 6-mercaptopurine-intolerant inflammatory bowel disease patients: a short-term safety assessment. Eur J Gastroenterol Hepatol. 2003;15(1):63–7.PubMedCrossRef
106.
van Asseldonk DP, Seinen ML, de Boer NK, et al. Hepatotoxicity associated with 6-methyl mercaptopurine formation during azathioprine and 6-mercaptopurine therapy does not occur on the short-term during 6-thioguanine therapy in IBD treatment. J Crohns Colitis. 2012;6(1):95–101.PubMedCrossRef
107.
Jharap B, de Boer N, Vos R, et al. Biotransformation of 6-thioguanine in inflammatory bowel disease patients: a comparison of oral and intravenous administration of 6-thioguanine. Br J Pharmacol. 2011;163(4):722–31.PubMedPubMedCentralCrossRef
108.
Brox LW, Birkett L, Belch A. Clinical pharmacology of oral thioguanine in acute myelogenous leukemia. Cancer Chemother Pharmacol. 1981;6(1):35–8.PubMedCrossRef
109.
Lancaster DL, Patel N, Lennard L, et al. 6-Thioguanine in children with acute lymphoblastic leukaemia: influence of food on parent drug pharmacokinetics and 6-thioguanine nucleotide concentrations. Br J Clin Pharmacol. 2001;51(6):531–9.PubMedPubMedCentralCrossRef
110.
Lennard L, Davies HA, Lilleyman JS. Is 6-thioguanine more appropriate than 6-mercaptopurine for children with acute lymphoblastic leukaemia? Br J Cancer. 1993;68(1):186–90.PubMedPubMedCentralCrossRef
111.
Sahasranaman S, Howard D, Roy S. Clinical pharmacology and pharmacogenetics of thiopurines. Eur J Clin Pharmacol. 2008;64(8):753–67.PubMedCrossRef
112.
Oancea I, Movva R, Das I, et al. Colonic microbiota can promote rapid local improvement of murine colitis by thioguanine independently of T lymphocytes and host metabolism. Gut. 2017;66(1):59–69.PubMedCrossRef
113.
Fairchild CR, Maybaum J, Kennedy KA. Concurrent unilateral chromatid damage and DNA strand breakage in response to 6-thioguanine treatment. Biochem Pharmacol. 1986;35(20):3533–41.PubMedCrossRef
114.
Tiede I, Fritz G, Strand S, et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+T lymphocytes. J Clin Invest. 2003;111(8):1133–45.PubMedPubMedCentralCrossRef
115.
Seinen ML, van Nieuw Amerongen GP, de Boer NK, et al. Rac1 as a potential pharmacodynamic biomarker for thiopurine therapy in inflammatory bowel disease. Ther Drug Monit. 2016;38(5):621–7.PubMedCrossRef
116.
Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology. 2000;118(4):705–13.PubMedCrossRef
117.
Dervieux T, Blanco JG, Krynetski EY, et al. Differing contribution of thiopurine methyltransferase to mercaptopurine versus thioguanine effects in human leukemic cells. Cancer Res. 2001;61(15):5810–6.PubMed
118.
Gilissen LP, Derijks LJ, Verhoeven HM, et al. Pancytopenia due to high 6-methylmercaptopurine levels in a 6-mercaptopurine treated patient with Crohn’s disease. Dig Liver Dis. 2007;39(2):182–6.PubMedCrossRef
119.
Meijer B, Kreijne JE, van Moorsel SA, et al. 6-methylmercaptopurine induced leukocytopenia during thiopurine therapy in IBD patients. J Gastroenterol Hepatol. 2017;32(6):1182–90.CrossRef
120.
121.
Lewis LD, Benin A, Szumlanski CL, et al. Olsalazine and 6-mercaptopurine-related bone marrow suppression: a possible drug-drug interaction. Clin Pharmacol Ther. 1997;62(4):464–75.PubMedCrossRef
122.
Lowry PW, Szumlanski CL, Weinshilboum RM, et al. Balsalazide and azathiprine or 6-mercaptopurine: evidence for a potentially serious drug interaction. Gastroenterology. 1999;116(6):1505–6.PubMedCrossRef
123.
Szumlanski CL, Weinshilboum RM. Sulphasalazine inhibition of thiopurine methyltransferase: possible mechanism for interaction with 6-mercaptopurine and azathioprine. Br J Clin Pharmacol. 1995;39(4):456–9.PubMedPubMedCentralCrossRef
124.
Dewit O, Vanheuverzwyn R, Desager JP, et al. Interaction between azathioprine and aminosalicylates: an in vivo study in patients with Crohn’s disease. Aliment Pharmacol Ther. 2002;16(1):79–85.PubMedCrossRef
125.
Gilissen LP, Bierau J, Derijks LJ, et al. The pharmacokinetic effect of discontinuation of mesalazine on mercaptopurine metabolite levels in inflammatory bowel disease patients. Aliment Pharmacol Ther. 2005;22(7):605–11.PubMedCrossRef
126.
de Boer NK, Wong DR, Jharap B, et al. Dose-dependent influence of 5-aminosalicylates on thiopurine metabolism. Am J Gastroenterol. 2007;102(12):2747–53.PubMedCrossRef
127.
Lowry PW, Franklin CL, Weaver AL, et al. Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide. Gut. 2001;49(5):656–64.PubMedPubMedCentralCrossRef
128.
Woodson LC, Ames MM, Selassie CD, et al. Thiopurine methyltransferase. Aromatic thiol substrates and inhibition by benzoic acid derivatives. Mol Pharmacol. 1983;24(3):471–8.PubMed
129.
Lysaa RA, Giverhaug T, Wold HL, et al. Inhibition of human thiopurine methyltransferase by furosemide, bendroflumethiazide and trichlormethiazide. Eur J Clin Pharmacol. 1996;49(5):393–6.PubMedCrossRef
130.
Kennedy DT, Hayney MS, Lake KD. Azathioprine and allopurinol: the price of an avoidable drug interaction. Ann Pharmacother. 1996;30(9):951–4.PubMedCrossRef
131.
Sanderson J, Ansari A, Marinaki T, et al. Thiopurine methyltransferase: should it be measured before commencing thiopurine drug therapy? Ann Clin Biochem. 2004;41(Pt 4):294–302.PubMedCrossRef
132.
Derijks LJ, Wong DR. Pharmacogenetics of thiopurines in inflammatory bowel disease. Curr Pharm Des. 2010;16(2):145–54.PubMedCrossRef
133.
Krynetski EY, Evans WE. Genetic polymorphism of thiopurine S-methyltransferase: molecular mechanisms and clinical importance. Pharmacology. 2000;61(3):136–46.PubMedCrossRef
134.
Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet. 1980;32(5):651–62.PubMedPubMedCentral
135.
Schaeffeler E, Lang T, Zanger UM, et al. High-throughput genotyping of thiopurine S-methyltransferase by denaturing HPLC. Clin Chem. 2001;47(3):548–55.PubMed
136.
Schaeffeler E, Fischer C, Brockmeier D, et al. Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants. Pharmacogenetics. 2004;14(7):407–17.PubMedCrossRef
137.
Hamdan-Khalil R, Gala JL, Allorge D, et al. Identification and functional analysis of two rare allelic variants of the thiopurine S-methyltransferase gene, TPMT*16 and TPMT*19. Biochem Pharmacol. 2005;69(3):525–9.PubMedCrossRef
138.
Schaeffeler E, Eichelbaum M, Reinisch W, et al. Three novel thiopurine S-methyltransferase allelic variants (TPMT*20, *21, *22)—association with decreased enzyme function. Hum Mutat. 2006;27(9):976.PubMedCrossRef
139.
Garat A, Cauffiez C, Renault N, et al. Characterisation of novel defective thiopurine S-methyltransferase allelic variants. Biochem Pharmacol. 2008;76(3):404–15.PubMedCrossRef
140.
Ujiie S, Sasaki T, Mizugaki M, et al. Functional characterization of 23 allelic variants of thiopurine S-methyltransferase gene (TPMT*2–*24). Pharmacogenet Genomics. 2008;18(10):887–93.PubMedCrossRef
141.
142.
Feng Q, Vannaprasaht S, Peng Y, et al. Thiopurine S-methyltransferase pharmacogenetics: functional characterization of a novel rapidly degraded variant allozyme. Biochem Pharmacol. 2010;79(7):1053–61.PubMedCrossRef
143.
Appell ML, Wennerstrand P, Peterson C, et al. Characterization of a novel sequence variant, TPMT*28, in the human thiopurine methyltransferase gene. Pharmacogenet Genomics. 2010;20(11):700–7.PubMedCrossRef
144.
145.
Weinshilboum R. Thiopurine pharmacogenetics: clinical and molecular studies of thiopurine methyltransferase. Drug Metab Dispos. 2001;29(4 Pt 2):601–5.PubMed
146.
Reuther LO, Sonne J, Larsen N, et al. Thiopurine methyltransferase genotype distribution in patients with Crohn’s disease. Aliment Pharmacol Ther. 2003;17(1):65–8.PubMedCrossRef
147.
Yates CR, Krynetski EY, Loennechen T, et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med. 1997;126(8):608–14.PubMedCrossRef
148.
Coulthard SA, Hall AG. Recent advances in the pharmacogenomics of thiopurine methyltransferase. Pharmacogenomics J. 2001;1(4):254–61.PubMedCrossRef
149.
Ansari A, Hassan C, Duley J, et al. Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease. Aliment Pharmacol Ther. 2002;16(10):1743–50.PubMedCrossRef
150.
Evans WE. Pharmacogenetics of thiopurine S-methyltransferase and thiopurine therapy. Ther Drug Monit. 2004;26(2):186–91.PubMedCrossRef
151.
Kurzawski M, Gawronska-Szklarz B, Drozdzik M. Frequency distribution of thiopurine S-methyltransferase alleles in a polish population. Ther Drug Monit. 2004;26(5):541–5.PubMedCrossRef
152.
Kubota T, Chiba K. Frequencies of thiopurine S-methyltransferase mutant alleles (TPMT*2, *3A, *3B and *3C) in 151 healthy Japanese subjects and the inheritance of TPMT*3C in the family of a propositus. Br J Clin Pharmacol. 2001;51(5):475–7.PubMedPubMedCentralCrossRef
153.
Ameyaw MM, Collie-Duguid ES, Powrie RH, et al. Thiopurine methyltransferase alleles in British and Ghanaian populations. Hum Mol Genet. 1999;8(2):367–70.PubMedCrossRef
154.
Collie-Duguid ES, Pritchard SC, Powrie RH, et al. The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations. Pharmacogenetics. 1999;9(1):37–42.PubMedCrossRef
155.
Pettersson B, Almer S, Albertioni F, et al. Differences between children and adults in thiopurine methyltransferase activity and metabolite formation during thiopurine therapy: possible role of concomitant methotrexate. Ther Drug Monit. 2002;24(3):351–8.PubMedCrossRef
156.
Indjova D, Atanasova S, Shipkova M, et al. Phenotypic and genotypic analysis of thiopurine s-methyltransferase polymorphism in the bulgarian population. Ther Drug Monit. 2003;25(5):631–6.PubMedCrossRef
157.
Dubinsky MC, Yang H, Hassard PV, et al. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology. 2002;122(4):904–15.PubMedCrossRef
158.
Coenen MJ, de Jong DJ, van Marrewijk CJ, et al. Identification of patients with variants in TPMT and dose reduction reduces hematologic events during thiopurine treatment of inflammatory bowel disease. Gastroenterology. 2015;149(4):907-17.e7.PubMedCrossRef
159.
160.
Seidman EG. Clinical use and practical application of TPMT enzyme and 6-mercaptopurine metabolite monitoring in IBD. Rev Gastroenterol Disord. 2003;3(Suppl 1):S30–8.PubMed
161.
Kaskas BA, Louis E, Hindorf U, et al. Safe treatment of thiopurine S-methyltransferase deficient Crohn’s disease patients with azathioprine. Gut. 2003;52(1):140–2.PubMedPubMedCentralCrossRef
162.
van Moorsel SA, Bevers N, Meurs M, et al. Azathioprine therapy in a pediatric TPMT—deficient patient—still an option. Ther Drug Monit. 2017;39(1):1–4.PubMedCrossRef
163.
Derijks LJ, van Helden RB, Hommes DW, et al. Dosing azathioprine in thiopurine S-methyltransferase deficient inflammatory bowel disease patients. Gut. 2008;57(6):872.PubMedCrossRef
164.
Mares WG, Wong DR, Gilissen LP, et al. Safe 6-thioguanine therapy of a TPMT deficient Crohn’s disease patient by using therapeutic drug monitoring. J Crohns Colitis. 2009;3(2):128–30.PubMedCrossRef
165.
Feuerstein JD, Nguyen GC, Kupfer SS, et al. American Gastroenterological Association Institute Guideline on therapeutic drug monitoring in inflammatory bowel disease. Gastroenterology. 2017;153(3):827–34.PubMedCrossRef
166.
Vande Casteele N, Herfarth H, Katz J, et al. American Gastroenterological Association Institute Technical Review on the Role of Therapeutic Drug Monitoring in the Management of Inflammatory Bowel Diseases. Gastroenterology. 2017;153(3):835-857.e6.PubMedCrossRef
167.
Colombel JF, Ferrari N, Debuysere H, et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn’s disease and severe myelosuppression during azathioprine therapy. Gastroenterology. 2000;118(6):1025–30.PubMedCrossRef
168.
Lennard L, Singleton HJ. High-performance liquid chromatographic assay of the methyl and nucleotide metabolites of 6-mercaptopurine: quantitation of red blood cell 6-thioguanine nucleotide, 6-thioinosinic acid and 6-methylmercaptopurine metabolites in a single sample. J Chromatogr. 1992;583(1):83–90.PubMedCrossRef
169.
Dervieux T, Boulieu R. Simultaneous determination of 6-thioguanine and methyl 6-mercaptopurine nucleotides of azathioprine in RBCs by HPLC. Clin Chem. 1998;44(3):551–5.PubMed
170.
Erdmann GR, France LA, Bostrom BC, et al. A reversed phase high performance liquid chromatography approach in determining total red blood cell concentrations of 6-thioguanine, 6-mercaptopurine, methylthioguanine, and methylmercaptopurine in a patient receiving thiopurine therapy. Biomed Chromatogr. 1990;4(2):47–51.PubMedCrossRef
171.
Armstrong VW, Shipkova M, von Ahsen N, et al. Analytic aspects of monitoring therapy with thiopurine medications. Ther Drug Monit. 2004;26(2):220–6.PubMedCrossRef
172.
Stefan C, Walsh W, Banka T, et al. Improved HPLC methodology for monitoring thiopurine metabolites in patients on thiopurine therapy. Clin Biochem. 2004;37(9):764–71.PubMedCrossRef
173.
Cuffari C, Theoret Y, Latour S, et al. 6-Mercaptopurine metabolism in Crohn’s disease: correlation with efficacy and toxicity. Gut. 1996;39(3):401–6.PubMedPubMedCentralCrossRef
174.
Cuffari C, Hunt S, Bayless T. Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease. Gut. 2001;48(5):642–6.PubMedPubMedCentralCrossRef
175.
Achkar JP, Stevens T, Easley K, et al. Indicators of clinical response to treatment with six-mercaptopurine or azathioprine in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2004;10(4):339–45.PubMedCrossRef
176.
Hindorf U, Lyrenas E, Nilsson A, et al. Monitoring of long-term thiopurine therapy among adults with inflammatory bowel disease. Scand J Gastroenterol. 2004;39(11):1105–12.PubMedCrossRef
177.
Belaiche J, Desager JP, Horsmans Y, et al. Therapeutic drug monitoring of azathioprine and 6-mercaptopurine metabolites in Crohn disease. Scand J Gastroenterol. 2001;36(1):71–6.PubMedCrossRef
178.
Lowry PW, Franklin CL, Weaver AL, et al. Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease. Gut. 2001;49(5):665–70.PubMedPubMedCentralCrossRef
179.
Gupta P, Gokhale R, Kirschner BS. 6-mercaptopurine metabolite levels in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2001;33(4):450–4.PubMedCrossRef
180.
Goldenberg BA, Rawsthorne P, Bernstein CN. The utility of 6-thioguanine metabolite levels in managing patients with inflammatory bowel disease. Am J Gastroenterol. 2004;99(9):1744–8.PubMedCrossRef
181.
Sandborn WJ. 6-MP metabolite levels: a potential guide to Crohn’s disease therapy. Gastroenterology. 1997;113(2):690–2.PubMedCrossRef
182.
Cohen RD. Forecast for using metabolite measurements in the dosing of azathioprine or 6-mercaptopurine for IBD patients: “partly cloudy”. Gastroenterology. 2002;122(7):2082–4 (discussion 2084).PubMedCrossRef
183.
Derijks LJ, Gilissen LP, Engels LG, et al. Pharmacokinetics of 6-mercaptopurine in patients with inflammatory bowel disease: implications for therapy. Ther Drug Monit. 2004;26(3):311–8.PubMedCrossRef
184.
Reinshagen M, Schutz E, Armstrong VW, et al. 6-Thioguanine nucleotide-adapted azathioprine therapy does not lead to higher remission rates than standard therapy in chronic active crohn disease: results from a randomized, controlled. Open Trial. Clin Chem. 2007;53(7):1306–14.PubMed
185.
van Asseldonk DP, Sanderson J, de Boer NK, et al. Difficulties and possibilities with thiopurine therapy in inflammatory bowel disease—proceedings of the first Thiopurine Task Force meeting. Dig Liver Dis. 2011;43(4):270–6.PubMedCrossRef
186.
Sparrow MP, Hande SA, Friedman S, et al. Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine. Aliment Pharmacol Ther. 2005;22(5):441–6.PubMedCrossRef
187.
Appell ML, Wagner A, Hindorf U. A skewed thiopurine metabolism is a common clinical phenomenon that can be successfully managed with a combination of low-dose azathioprine and allopurinol. J Crohns Colitis. 2013;7(6):510–3.PubMedCrossRef
188.
Gardiner SJ, Gearry RB, Burt MJ, et al. Allopurinol might improve response to azathioprine and 6-mercaptopurine by correcting an unfavorable metabolite ratio. J Gastroenterol Hepatol. 2011;26(1):49–54.PubMedCrossRef
189.
Hoentjen F, Seinen ML, Hanauer SB, et al. Safety and effectiveness of long-term allopurinol-thiopurine maintenance treatment in inflammatory bowel disease. Inflamm Bowel Dis. 2013;19(2):363–9.PubMedCrossRef
190.
Seinen ML, van Asseldonk DP, de Boer NK, et al. The effect of allopurinol and low-dose thiopurine combination therapy on the activity of three pivotal thiopurine metabolizing enzymes: results from a prospective pharmacological study. J Crohns Colitis. 2013;7(10):812–9.PubMedCrossRef
191.
Duley JA, Chocair PR, Florin TH. Observations on the use of allopurinol in combination with azathioprine or mercaptopurine. Aliment Pharmacol Ther. 2005;22(11–12):1161–2.PubMedCrossRef
192.
Blaker PA, Arenas-Hernandez M, Smith MA, et al. Mechanism of allopurinol induced TPMT inhibition. Biochem Pharmacol. 2013;86(4):539–47.PubMedCrossRef
193.
Wong DR, Coenen MJ, Vermeulen SH, et al. Early Assessment of Thiopurine Metabolites Identifies Patients at Risk of Thiopurine-induced Leukopenia in Inflammatory Bowel Disease. J Crohns Colitis. 2017;11(2):175–84.
194.
Wong DR, Coenen MJ, Derijks LJ, et al. Early prediction of thiopurine-induced hepatotoxicity in inflammatory bowel disease. Aliment Pharmacol Ther. 2017;45(3):391–402.PubMedCrossRef
195.
Baert F, Rutgeerts P. 6-Thioguanine: a naked bullet? (Or how pharmacogenomics can make old drugs brand new). Inflamm Bowel Dis. 2001;7(3):190–1.PubMedCrossRef
196.
Lancaster DL, Patel N, Lennard L, et al. Leucocyte versus erythrocyte thioguanine nucleotide concentrations in children taking thiopurines for acute lymphoblastic leukaemia. Cancer Chemother Pharmacol. 2002;50(1):33–6.PubMedCrossRef
197.
Herrlinger KR, Deibert P, Schwab M, et al. Remission maintenance by tioguanine in chronic active Crohn’s disease. Aliment Pharmacol Ther. 2003;17(12):1459–64.PubMedCrossRef
198.
de Boer NK, Derijks LJ, Gilissen LP, et al. On tolerability and safety of a maintenance treatment with 6-thioguanine in azathioprine or 6-mercaptopurine intolerant IBD patients. World J Gastroenterol. 2005;11(35):5540–4.PubMedPubMedCentralCrossRef
199.
Dubinsky MC, Vasiliauskas EA, Singh H, et al. 6-Thioguanine can cause serious liver injury in inflammatory bowel disease patients. Gastroenterology. 2003;125(2):298–303.PubMedCrossRef
200.
Geller SA, Dubinsky MC, Poordad FF, et al. Early hepatic nodular hyperplasia and submicroscopic fibrosis associated with 6-thioguanine therapy in inflammatory bowel disease. Am J Surg Pathol. 2004;28(9):1204–11.PubMedCrossRef
201.
Naber AH, Van Haelst U, Yap SH. Nodular regenerative hyperplasia of the liver: an important cause of portal hypertension in non-cirrhotic patients. J Hepatol. 1991;12(1):94–9.PubMedCrossRef
202.
Stromeyer FW, Ishak KG. Nodular transformation (nodular “regenerative” hyperplasia) of the liver. A clinicopathologic study of 30 cases. Hum Pathol. 1981;12(1):60–71.PubMedCrossRef
203.
Seinen ML, van Asseldonk DP, de Boer NK, et al. Nodular regenerative hyperplasia of the liver in patients with IBD treated with allopurinol-thiopurine combination therapy. Inflamm Bowel Dis. 2017;23(3):448–52.PubMedCrossRef
204.
de Boer NK, Reinisch W, Teml A, et al. 6-Thioguanine treatment in inflammatory bowel disease: a critical appraisal by a European 6-TG working party. Digestion. 2006;73(1):25–31.PubMedCrossRef
205.
Vernier-Massouille G, Cosnes J, Lemann M, et al. Nodular regenerative hyperplasia in patients with inflammatory bowel disease treated with azathioprine. Gut. 2007;56(10):1404–9.PubMedPubMedCentralCrossRef
206.
Ferlitsch A, Teml A, Reinisch W, et al. 6-Thioguanine associated nodular regenerative hyperplasia in patients with inflammatory bowel disease may induce portal hypertension. Am J Gastroenterol. 2007;102(11):2495–503.PubMedCrossRef
207.
van Asseldonk DP, Jharap B, Verheij J, et al. The prevalence of nodular regenerative hyperplasia in inflammatory bowel disease patients treated with thioguanine is not associated with clinically significant liver disease. Inflamm Bowel Dis. 2016;22(9):2112–20.PubMedCrossRef
208.
Jharap B, van Asseldonk DP, de Boer NK, et al. Diagnosing nodular regenerative hyperplasia of the liver is thwarted by low interobserver agreement. PLoS One. 2015;10(6):e0120299.PubMedPubMedCentralCrossRef
209.
Derijks LJ, Gilissen LP, de Boer NK, et al. 6-Thioguanine-related hepatotoxicity in patients with inflammatory bowel disease: dose or level dependent? J Hepatol. 2006;44(4):821–2.PubMedCrossRef
210.
Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohn’s disease. The North American Crohn’s Study Group Investigators. N Engl J Med. 1995;332(5):292–7.PubMedCrossRef
211.
Feagan BG, Fedorak RN, Irvine EJ, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn’s disease. North American Crohn’s Study Group Investigators. N Engl J Med. 2000;342(22):1627–32.PubMedCrossRef
212.
McDonald JW, Wang Y, Tsoulis DJ, et al. Methotrexate for induction of remission in refractory Crohn’s disease. Cochrane Database Syst Rev. 2014;8:CD003459.
213.
Carbonnel F, Colombel JF, Filippi J, et al. Methotrexate is not superior to placebo for inducing steroid-free remission, but induces steroid-free clinical remission in a larger proportion of patients with ulcerative colitis. Gastroenterology. 2016;150(2):380-8.e4.PubMedCrossRef
214.
Oren R, Moshkowitz M, Odes S, et al. Methotrexate in chronic active Crohn’s disease: a double-blind, randomized. Israeli multicenter trial. Am J Gastroenterol. 1997;92(12):2203–9.PubMed
215.
Arora S, Katkov W, Cooley J, et al. Methotrexate in Crohn’s disease: results of a randomized, double-blind, placebo-controlled trial. Hepatogastroenterology. 1999;46(27):1724–9.PubMed
216.
Seinen ML, Ponsioen CY, de Boer NK, et al. Sustained clinical benefit and tolerability of methotrexate monotherapy after thiopurine therapy in patients with Crohn’s disease. Clin Gastroenterol Hepatol. 2013;11(6):667–72.PubMedCrossRef
217.
Teresi ME, Crom WR, Choi KE, et al. Methotrexate bioavailability after oral and intramuscular administration in children. J Pediatr. 1987;110(5):788–92.PubMedCrossRef
218.
Pinkerton CR, Glasgow JF, Bridges JM, et al. Enterotoxic effect of methotrexate: does it influence the drug’s absorption in children with acute lymphoblastic leukaemia? Br Med J (Clin Res Ed). 1981;282(6272):1276–7.PubMedCentralCrossRef
219.
Egan LJ, Sandborn WJ, Mays DC, et al. Systemic and intestinal pharmacokinetics of methotrexate in patients with inflammatory bowel disease. Clin Pharmacol Ther. 1999;65(1):29–39.PubMedCrossRef
220.
McGuire JJ, Hsieh P, Bertino JR. Enzymatic synthesis of polyglutamate derivatives of 7-hydroxymethotrexate. Biochem Pharmacol. 1984;33(8):1355–61.PubMedCrossRef
221.
Schmiegelow K. Advances in individual prediction of methotrexate toxicity: a review. Br J Haematol. 2009;146(5):489–503.PubMedCrossRef
222.
Grim J, Chladek J, Martinkova J. Pharmacokinetics and pharmacodynamics of methotrexate in non-neoplastic diseases. Clin Pharmacokinet. 2003;42(2):139–51.PubMedCrossRef
223.
Shen DD, Azarnoff DL. Clinical pharmacokinetics of methotrexate. Clin Pharmacokinet. 1978;3(1):1–13.PubMedCrossRef
224.
Brown PM, Pratt AG, Isaacs JD. Mechanism of action of methotrexate in rheumatoid arthritis, and the search for biomarkers. Nat Rev Rheumatol. 2016;12(12):731–42.PubMedCrossRef
225.
Egan LJ, Sandborn WJ. Methotrexate for inflammatory bowel disease: pharmacology and preliminary results. Mayo Clin Proc. 1996;71(1):69–80.PubMedCrossRef
226.
Edno L, Bressolle F, Gomeni R, et al. Total and free methotrexate pharmacokinetics in rheumatoid arthritis patients. Ther Drug Monit. 1996;18(2):128–34.PubMedCrossRef
227.
Weinblatt ME, Maier AL, Coblyn JS. Low dose leucovorin does not interfere with the efficacy of methotrexate in rheumatoid arthritis: an 8 week randomized placebo controlled trial. J Rheumatol. 1993;20(6):950–2.PubMed
228.
Herrlinger KR, Cummings JR, Barnardo MC, et al. The pharmacogenetics of methotrexate in inflammatory bowel disease. Pharmacogenet Genomics. 2005;15(10):705–11.PubMedCrossRef
229.
Ahern M, Booth J, Loxton A, et al. Methotrexate kinetics in rheumatoid arthritis: is there an interaction with nonsteroidal antiinflammatory drugs? J Rheumatol. 1988;15(9):1356–60.PubMed
230.
Basin KS, Escalante A, Beardmore TD. Severe pancytopenia in a patient taking low dose methotrexate and probenecid. J Rheumatol. 1991;18(4):609–10.PubMed
231.
Govert JA, Patton S, Fine RL. Pancytopenia from using trimethoprim and methotrexate. Ann Intern Med. 1992;117(10):877–8.PubMedCrossRef
232.
Al-Awadhi A, Dale P, McKendry RJ. Pancytopenia associated with low dose methotrexate therapy. A regional survey. J Rheumatol. 1993;20(7):1121–5.PubMed
233.
Al-Quteimat OM, Al-Badaineh MA. Methotrexate and trimethoprim-sulphamethoxazole: extremely serious and life-threatening combination. J Clin Pharm Ther. 2013;38(3):203–5.PubMedCrossRef
234.
Moskovitz DN, Van Assche G, Maenhout B, et al. Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis. Clin Gastroenterol Hepatol. 2006;4(6):760–5.PubMedCrossRef
235.
Campbell S, Travis S, Jewell D. Ciclosporin use in acute ulcerative colitis: a long-term experience. Eur J Gastroenterol Hepatol. 2005;17(1):79–84.PubMedCrossRef
236.
Bamba S, Tsujikawa T, Inatomi O, et al. Factors affecting the efficacy of cyclosporin A therapy for refractory ulcerative colitis. J Gastroenterol Hepatol. 2010;25(3):494–8.PubMedCrossRef
237.
Walch A, Meshkat M, Vogelsang H, et al. Long-term outcome in patients with ulcerative colitis treated with intravenous cyclosporine A is determined by previous exposure to thiopurines. J Crohns Colitis. 2010;4(4):398–404.PubMedCrossRef
238.
Feagan BG, McDonald JW, Rochon J, et al. Low-dose cyclosporine for the treatment of Crohn’s disease. The Canadian Crohn’s Relapse Prevention Trial Investigators. N Engl J Med. 1994;330(26):1846–51.PubMedCrossRef
239.
240.
Stange EF, Modigliani R, Pena AS, et al. European trial of cyclosporine in chronic active Crohn’s disease: a 12-month study. The European Study Group. Gastroenterology. 1995;109(3):774–82.PubMedCrossRef
241.
Santos JV, Baudet JA, Casellas FJ, et al. Intravenous cyclosporine for steroid-refractory attacks of Crohn’s disease. Short- and long-term results. J Clin Gastroenterol. 1995;20(3):207–10.PubMedCrossRef
242.
Sandborn WJ, Present DH, Isaacs KL, et al. Tacrolimus for the treatment of fistulas in patients with Crohn’s disease: a randomized, placebo-controlled trial. Gastroenterology. 2003;125(2):380–8.PubMedCrossRef
243.
Schreiber SL, Crabtree GR. The mechanism of action of cyclosporin A and FK506. Immunol Today. 1992;13(4):136–42.PubMedCrossRef
244.
245.
Friman S, Backman L. A new microemulsion formulation of cyclosporin: pharmacokinetic and clinical features. Clin Pharmacokinet. 1996;30(3):181–93.PubMedCrossRef
246.
Noble S, Markham A. Cyclosporin. A review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (Neoral). Drugs. 1995;50(5):924–41.PubMedCrossRef
247.
Wallemacq PE, Lhoest G, Latinne D, et al. Isolation, characterization and in vitro activity of human cyclosporin A metabolites. Transplant Proc. 1989;21(1 Pt 1):906–10.PubMed
248.
Saeki T, Ueda K, Tanigawara Y, et al. Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem. 1993;268(9):6077–80.PubMed
249.
Lown KS, Mayo RR, Leichtman AB, et al. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther. 1997;62(3):248–60.PubMedCrossRef
250.
Brynskov J, Freund L, Campanini MC, et al. Cyclosporin pharmacokinetics after intravenous and oral administration in patients with Crohn’s disease. Scand J Gastroenterol. 1992;27(11):961–7.PubMedCrossRef
251.
Yee GC, McGuire TR. Pharmacokinetic drug interactions with cyclosporin (Part I). Clin Pharmacokinet. 1990;19(4):319–32.PubMedCrossRef
252.
Yee GC, McGuire TR. Pharmacokinetic drug interactions with cyclosporin (Part II). Clin Pharmacokinet. 1990;19(5):400–15.PubMedCrossRef
253.
Gomez DY, Wacher VJ, Tomlanovich SJ, et al. The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. Clin Pharmacol Ther. 1995;58(1):15–9.PubMedCrossRef
254.
Michalets EL. Update: clinically significant cytochrome P-450 drug interactions. Pharmacotherapy. 1998;18(1):84–112.PubMed
255.
Ameer B, Weintraub RA. Drug interactions with grapefruit juice. Clin Pharmacokinet. 1997;33(2):103–21.PubMedCrossRef
256.
Hebert MF, Roberts JP, Prueksaritanont T, et al. Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clin Pharmacol Ther. 1992;52(5):453–7.PubMedCrossRef
257.
Greeson JM, Sanford B, Monti DA. St. John’s wort (Hypericum perforatum): a review of the current pharmacological, toxicological, and clinical literature. Psychopharmacology (Berl). 2001;153(4):402–14.CrossRef
258.
Van Assche G, D’Haens G, Noman M, et al. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology. 2003;125(4):1025–31.PubMedCrossRef
259.
Plosker GL, Foster RH. Tacrolimus: a further update of its pharmacology and therapeutic use in the management of organ transplantation. Drugs. 2000;59(2):323–89.PubMedCrossRef
260.
Nagase K, Iwasaki K, Nozaki K, et al. Distribution and protein binding of FK506, a potent immunosuppressive macrolide lactone, in human blood and its uptake by erythrocytes. J Pharm Pharmacol. 1994;46(2):113–7.PubMedCrossRef
261.
Venkataramanan R, Swaminathan A, Prasad T, et al. Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet. 1995;29(6):404–30.PubMedCrossRef
262.
Kelly P, Kahan BD. Review: metabolism of immunosuppressant drugs. Curr Drug Metab. 2002;3(3):275–87.PubMedCrossRef
263.
Moller A, Iwasaki K, Kawamura A, et al. The disposition of 14C-labeled tacrolimus after intravenous and oral administration in healthy human subjects. Drug Metab Dispos. 1999;27(6):633–6.PubMed
264.
Bhaloo S, Prasad GV. Severe reduction in tacrolimus levels with rifampin despite multiple cytochrome P450 inhibitors: a case report. Transplant Proc. 2003;35(7):2449–51.PubMedCrossRef
265.
Hebert MF, Lam AY. Diltiazem increases tacrolimus concentrations. Ann Pharmacother. 1999;33(6):680–2.PubMedCrossRef
266.
Mignat C. Clinically significant drug interactions with new immunosuppressive agents. Drug Saf. 1997;16(4):267–78.PubMedCrossRef
267.
Ogata H, Matsui T, Nakamura M, et al. A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut. 2006;55(9):1255–62.PubMedPubMedCentralCrossRef
268.
Hiraoka S, Kato J, Moritou Y, et al. The earliest trough concentration predicts the dose of tacrolimus required for remission induction therapy in ulcerative colitis patients. BMC Gastroenterol. 2015;15:53-015-0285-3.CrossRef
269.
van Dullemen HM, van Deventer SJ, Hommes DW, et al. Treatment of Crohn’s disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology. 1995;109(1):129–35.PubMedCrossRef
270.
Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Group. N Engl J Med. 1997;337(15):1029–35.PubMedCrossRef
271.
Baert FJ, D’Haens GR, Peeters M, et al. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn’s ileocolitis. Gastroenterology. 1999;116(1):22–8.PubMedCrossRef
272.
Rutgeerts P, Vermeire S, Van Assche G. Biological therapies for inflammatory bowel diseases. Gastroenterology. 2009;136(4):1182–97.PubMedCrossRef
273.
Nesbitt A, Fossati G, Bergin M, et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm Bowel Dis. 2007;13(11):1323–32.PubMedCrossRef
274.
Vos AC, Wildenberg ME, Duijvestein M, et al. Anti-tumor necrosis factor-alpha antibodies induce regulatory macrophages in an Fc region-dependent manner. Gastroenterology. 2011;140(1):221–30.PubMedCrossRef
275.
Ordas I, Mould DR, Feagan BG, et al. Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms. Clin Pharmacol Ther. 2012;91(4):635–46.PubMedCrossRef
276.
Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002;359(9317):1541–9.PubMedCrossRef
277.
Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med. 2004;350(9):876–85.PubMedCrossRef
278.
Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353(23):2462–76.PubMedCrossRef
279.
Lichtenstein GR, Yan S, Bala M, et al. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn’s disease. Gastroenterology. 2005;128(4):862–9.PubMedCrossRef
280.
Jeuring SF, van den Heuvel TR, Liu LY, et al. Improvements in the long-term outcome of Crohn’s disease over the past two decades and the relation to changes in medical management: results from the Population-Based IBDSL Cohort. Am J Gastroenterol. 2017;112(2):325–36.PubMedCrossRef
281.
Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology. 2006;130(2):323–33 (quiz 591).PubMedCrossRef
282.
Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial. Gut. 2007;56(9):1232–9.PubMedPubMedCentralCrossRef
283.
Reinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut. 2011;60(6):780–7.PubMedCrossRef
284.
Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012;142(2):257-65.e1-3.PubMedCrossRef
285.
Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014;146(1):85–95 (quiz e14–5).PubMedCrossRef
286.
Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014;146(1):96-109.e1.PubMed
287.
Martineau C, Flourie B, Wils P, et al. Efficacy and safety of golimumab in Crohn’s disease: a French national retrospective study. Aliment Pharmacol Ther. 2017;46(11–12):1077–84.PubMedCrossRef
288.
Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn’s disease. N Engl J Med. 2007;357(3):228–38.PubMedCrossRef
289.
Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn’s disease. N Engl J Med. 2007;357(3):239–50.PubMedCrossRef
290.
Bendtzen K, Ainsworth M, Steenholdt C, et al. Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies. Scand J Gastroenterol. 2009;44(7):774–81.PubMedCrossRef
291.
Porter CJ, Charman SA. Lymphatic transport of proteins after subcutaneous administration. J Pharm Sci. 2000;89(3):297–310.PubMedCrossRef
292.
Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci. 2004;93(11):2645–68.PubMedCrossRef
293.
294.
Mould DR, Green B. Pharmacokinetics and pharmacodynamics of monoclonal antibodies: concepts and lessons for drug development. BioDrugs. 2010;24(1):23–39.PubMedCrossRef
295.
Klotz U, Teml A, Schwab M. Clinical pharmacokinetics and use of infliximab. Clin Pharmacokinet. 2007;46(8):645–60.PubMedCrossRef
296.
Dirks NL, Meibohm B. Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010;49(10):633–59.PubMedCrossRef
297.
Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2008;84(5):548–58.PubMedCrossRef
298.
Comber PG, Gomez F, Rossman MD, et al. Receptors for the Fc portion of immunoglobulin G (Fc gamma R) on human monocytes and macrophages. Prog Clin Biol Res. 1989;297:273–85.PubMed
299.
Cohen-Solal JF, Cassard L, Fridman WH, et al. Fc gamma receptors. Immunol Lett. 2004;92(3):199–205.PubMedCrossRef
300.
Louis E, El Ghoul Z, Vermeire S, et al. Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn’s disease. Aliment Pharmacol Ther. 2004;19(5):511–9.PubMedCrossRef
301.
Brambell FW, Hemmings WA, Morris IG. A theoretical model of gamma-globulin catabolism. Nature. 1964;203:1352–4.PubMedCrossRef
302.
Telleman P, Junghans RP. The role of the Brambell receptor (FcRB) in liver: protection of endocytosed immunoglobulin G (IgG) from catabolism in hepatocytes rather than transport of IgG to bile. Immunology. 2000;100(2):245–51.PubMedPubMedCentralCrossRef
303.
304.
Ternant D, Paintaud G. Pharmacokinetics and concentration-effect relationships of therapeutic monoclonal antibodies and fusion proteins. Expert Opin Biol Ther. 2005;5(Suppl 1):S37–47.PubMedCrossRef
305.
Cornillie F, Shealy D, D’Haens G, et al. Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn’s disease. Aliment Pharmacol Ther. 2001;15(4):463–73.PubMedCrossRef
306.
Weisman MH, Moreland LW, Furst DE, et al. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. Clin Ther. 2003;25(6):1700–21.PubMedCrossRef
307.
Olsen T, Goll R, Cui G, et al. TNF-alpha gene expression in colorectal mucosa as a predictor of remission after induction therapy with infliximab in ulcerative colitis. Cytokine. 2009;46(2):222–7.PubMedCrossRef
308.
Takeuchi T, Miyasaka N, Tatsuki Y, et al. Baseline tumour necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70(7):1208–15.PubMedPubMedCentralCrossRef
309.
Beeken WL, Busch HJ, Sylwester DL. Intestinal protein loss in Crohn’s disease. Gastroenterology. 1972;62(2):207–15.PubMed
310.
Kapel N, Meillet D, Favennec L, et al. Evaluation of intestinal clearance and faecal excretion of alpha 1-antiproteinase and immunoglobulins during Crohn’s disease and ulcerative colitis. Eur J Clin Chem Clin Biochem. 1992;30(4):197–202.PubMed
311.
Brandse JF, van den Brink GR, Wildenberg ME, et al. Loss of Infliximab Into Feces Is Associated With Lack of Response to Therapy in Patients With Severe Ulcerative Colitis. Gastroenterology. 2015;149(2):350-5.e2.PubMedCrossRef
312.
Schellekens H. Bioequivalence and the immunogenicity of biopharmaceuticals. Nat Rev Drug Discov. 2002;1(6):457–62.PubMedCrossRef
313.
Ternant D, Aubourg A, Magdelaine-Beuzelin C, et al. Infliximab pharmacokinetics in inflammatory bowel disease patients. Ther Drug Monit. 2008;30(4):523–9.PubMed
314.
Seow CH, Newman A, Irwin SP, et al. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut. 2010;59(1):49–54.PubMedCrossRef
315.
Maser EA, Villela R, Silverberg MS, et al. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn’s disease. Clin Gastroenterol Hepatol. 2006;4(10):1248–54.PubMedCrossRef
316.
Chiu YL, Rubin DT, Vermeire S, et al. Serum adalimumab concentration and clinical remission in patients with Crohn’s disease. Inflamm Bowel Dis. 2013;19(6):1112–22.PubMedCrossRef
317.
Mazor Y, Almog R, Kopylov U, et al. Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn’s disease. Aliment Pharmacol Ther. 2014;40(6):620–8.PubMedCrossRef
318.
Vande Casteele N, Gils A, Singh S, et al. Antibody response to infliximab and its impact on pharmacokinetics can be transient. Am J Gastroenterol. 2013;108(6):962–71.PubMedCrossRef
319.
Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N Engl J Med. 2003;348(7):601–8.PubMedCrossRef
320.
Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010;362(15):1383–95.PubMedCrossRef
321.
Vermeire S, Noman M, Van Assche G, et al. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn’s disease. Gut. 2007;56(9):1226–31.PubMedPubMedCentralCrossRef
322.
Ben-Horin S, Waterman M, Kopylov U, et al. Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013;11(4):444–7.PubMedCrossRef
323.
Khanna R, Sattin BD, Afif W, et al. Review article: a clinician’s guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease. Aliment Pharmacol Ther. 2013;38(5):447–59.PubMedCrossRef
324.
Roblin X, Boschetti G, Williet N, et al. Azathioprine dose reduction in inflammatory bowel disease patients on combination therapy: an open-label, prospective and randomised clinical trial. Aliment Pharmacol Ther. 2017;46(2):142–9.PubMedCrossRef
325.
Yarur AJ, Kubiliun MJ, Czul F, et al. Concentrations of 6-thioguanine nucleotide correlate with trough levels of infliximab in patients with inflammatory bowel disease on combination therapy. Clin Gastroenterol Hepatol. 2015;13(6):1118-24.e3.PubMedCrossRef
326.
Watanabe K, Matsumoto T, Hisamatsu T, et al. Clinical and pharmacokinetic factors associated with adalimumab-induced mucosal healing in patients with Crohn’s disease. Clin Gastroenterol Hepatol. 2018 [Epub ahead of print].
327.
Nakase H, Motoya S, Matsumoto T, et al. Significance of measurement of serum trough level and anti-drug antibody of adalimumab as personalised pharmacokinetics in patients with Crohn’s disease: a subanalysis of the DIAMOND trial. Aliment Pharmacol Ther. 2017;46(9):873–82.PubMedPubMedCentralCrossRef
328.
Adedokun OJ, Xu Z, Marano CW, et al. Pharmacokinetics and exposure-response relationship of golimumab in patients with moderately-to-severely active ulcerative colitis: results from phase 2/3 PURSUIT induction and maintenance studies. J Crohns Colitis. 2017;11(1):35–46.PubMedCrossRef
329.
Colombel JF, Sandborn WJ, Allez M, et al. Association between plasma concentrations of certolizumab pegol and endoscopic outcomes of patients with Crohn’s disease. Clin Gastroenterol Hepatol. 2014;12(3):423-31.e1.PubMed
330.
Papamichael K, Cheifetz AS. Therapeutic drug monitoring in IBD: the new standard-of-care for anti-TNF therapy. Am J Gastroenterol. 2017;112(5):673–6.PubMedCrossRef
331.
American Gastroenterological Association. Therapeutic drug monitoring in inflammatory bowel disease: clinical decision support tool. Gastroenterology. 2017;153(3):858–9.CrossRef
332.
Mitrev N, Vande Casteele N, Seow CH, et al. Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases. Aliment Pharmacol Ther. 2017;46(11–12):1037–53.PubMedCrossRef
333.
Roblin X, Rinaudo M, Del Tedesco E, et al. Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases. Am J Gastroenterol. 2014;109(8):1250–6.PubMedCrossRef
334.
Steenholdt C, Brynskov J, Thomsen OO, et al. Individualised therapy is more cost-effective than dose intensification in patients with Crohn’s disease who lose response to anti-TNF treatment: a randomised, controlled trial. Gut. 2014;63(6):919–27.PubMedCrossRef
335.
Vaughn BP, Sandborn WJ, Cheifetz AS. Biologic concentration testing in inflammatory bowel disease. Inflamm Bowel Dis. 2015;21(6):1435–42.PubMedPubMedCentral
336.
337.
Vande Casteele N, Ferrante M, Van Assche G, et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology. 2015;148(7):1320-9.e3.PubMedCrossRef
338.
Ungar B, Levy I, Yavne Y, et al. Optimizing Anti-TNF-alpha Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2016;14(4):550-557.e2.PubMedCrossRef
339.
Yarur AJ, Kanagala V, Stein DJ, et al. Higher infliximab trough levels are associated with perianal fistula healing in patients with Crohn’s disease. Aliment Pharmacol Ther. 2017;45(7):933–40.PubMedCrossRef
340.
Paul S, Moreau AC, Del Tedesco E, et al. Pharmacokinetics of adalimumab in inflammatory bowel diseases: a systematic review and meta-analysis. Inflamm Bowel Dis. 2014;20(7):1288–95.PubMedCrossRef
341.
Bodini G, Giannini EG, Savarino V, et al. Adalimumab trough serum levels and anti-adalimumab antibodies in the long-term clinical outcome of patients with Crohn’s disease. Scand J Gastroenterol. 2016;51(9):1081–6.PubMedCrossRef
342.
Detrez I, Dreesen E, Van Stappen T, et al. Variability in golimumab exposure: a ‘Real-Life’ observational study in active ulcerative colitis. J Crohns Colitis. 2016;10(5):575–81.PubMedPubMedCentralCrossRef
343.
Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369(8):699–710.PubMedCrossRef
344.
Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2013;369(8):711–21.PubMedCrossRef
345.
Rosario M, Dirks NL, Milch C, et al. A Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Vedolizumab. Clin Pharmacokinet. 2017;56(11):1287–301.
346.
Bye WA, Jairath V, Travis SPL. Systematic review: the safety of vedolizumab for the treatment of inflammatory bowel disease. Aliment Pharmacol Ther. 2017;46(1):3–15.PubMedCrossRef
347.
Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med. 2012;366(20):1870–80.PubMedCrossRef
348.
Berger JR. Natalizumab and progressive multifocal leucoencephalopathy. Ann Rheum Dis. 2006;65(Suppl 3):iii48–53.PubMedPubMedCentral
349.
Wyant T, Fedyk E, Abhyankar B. An overview of the mechanism of action of the monoclonal antibody vedolizumab. J Crohns Colitis. 2016;10(12):1437–44.PubMedCrossRef
350.
Rosario M, Dirks NL, Gastonguay MR, et al. Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn’s disease. Aliment Pharmacol Ther. 2015;42(2):188–202.PubMedPubMedCentralCrossRef
351.
Milch C, Wyant T, Xu J, et al. Vedolizumab, a monoclonal antibody to the gut homing alpha4beta7 integrin, does not affect cerebrospinal fluid T-lymphocyte immunophenotype. J Neuroimmunol. 2013;264(1–2):123–6.PubMedCrossRef
352.
Rosario M, French JL, Dirks NL, et al. Exposure-Efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn’s Disease. J Crohns Colitis. 2018 [Epub ahead of print].
353.
Dreesen E, Gils A. Blocking the 47 integrin through vedolizumab: Necessary but not sufficient? J Crohns Colitis. 2017;11(8):903–4.
354.
Feagan BG, Sandborn WJ, Gasink C, et al. Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease. N Engl J Med. 2016;375(20):1946–60.PubMedCrossRef
355.
Lamb YN, Duggan ST. Ustekinumab: a review in moderate to severe Crohn’s disease. Drugs. 2017;77(10):1105–14.PubMedCrossRef
356.
Simon EG, Samuel S, Ghosh S, et al. Ustekinumab: a novel therapeutic option in Crohn’s disease. Expert Opin Biol Ther. 2016;16(8):1065–74.PubMedCrossRef
357.
Monteleone G, Biancone L, Marasco R, et al. Interleukin 12 is expressed and actively released by Crohn’s disease intestinal lamina propria mononuclear cells. Gastroenterology. 1997;112(4):1169–78.PubMedCrossRef
358.
Duerr RH, Taylor KD, Brant SR, et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science. 2006;314(5804):1461–3.PubMedPubMedCentralCrossRef
359.
Deepak P, Loftus EV Jr. Ustekinumab in treatment of Crohn’s disease: design, development, and potential place in therapy. Drug Des Devel Ther. 2016;10:3685–98.PubMedPubMedCentralCrossRef
360.
Sandborn WJ, Gasink C, Gao LL, et al. Ustekinumab induction and maintenance therapy in refractory Crohn’s disease. N Engl J Med. 2012;367(16):1519–28.PubMedCrossRef
361.
362.
Derijks LJ, Hommes DW. Thiopurines in inflammatory bowel disease: new strategies for optimization of pharmacotherapy? Curr Gastroenterol Rep. 2006;8(2):89–92.PubMedCrossRef
363.
364.
Harzallah I, Rigaill J, Williet N, et al. Golimumab pharmacokinetics in ulcerative colitis: a literature review. Therap Adv Gastroenterol. 2017;10(1):89–100.PubMedCrossRef
365.
366.
367.
368.
Wade JR, Parker G, Kosutic G, et al. Population pharmacokinetic analysis of certolizumab pegol in patients with Crohn’s disease. J Clin Pharmacol. 2015;55(8):866–74.PubMedCrossRef
369.
Fasanmade AA, Adedokun OJ, Blank M, et al. Pharmacokinetic properties of infliximab in children and adults with Crohn’s disease: a retrospective analysis of data from 2 phase III clinical trials. Clin Ther. 2011;33(7):946–64.PubMedCrossRef
370.
Fasanmade AA, Adedokun OJ, Ford J, et al. Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis. Eur J Clin Pharmacol. 2009;65(12):1211–28.PubMedPubMedCentralCrossRef
371.
Adedokun OJ, Sandborn WJ, Feagan BG, et al. Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis. Gastroenterology. 2014;147(6):1296-1307.e5.PubMedCrossRef
372.
Cornillie F, Hanauer SB, Diamond RH, et al. Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial. Gut. 2014;63(11):1721–7.PubMedPubMedCentralCrossRef
373.
Reinisch W, Colombel JF, Sandborn WJ, et al. Factors associated with short- and long-term outcomes of therapy for Crohn’s disease. Clin Gastroenterol Hepatol. 2015;13(3):539-547.e2.PubMedCrossRef
374.
Warman A, Straathof JW, Derijks LJ. Therapeutic drug monitoring of infliximab in inflammatory bowel disease patients in a teaching hospital setting: results of a prospective cohort study. Eur J Gastroenterol Hepatol. 2015;27(3):242–8.PubMedCrossRef
375.
Roblin X, Boschetti G, Duru G, et al. Distinct Thresholds of Infliximab Trough Level Are Associated with Different Therapeutic Outcomes in Patients with Inflammatory Bowel Disease: A Prospective Observational Study. Inflamm Bowel Dis. 2017;23(11):2048–53.PubMedCrossRef
376.
Baert F, Kondragunta V, Lockton S, et al. Antibodies to adalimumab are associated with future inflammation in Crohn’s patients receiving maintenance adalimumab therapy: a post hoc analysis of the Karmiris trial. Gut. 2016;65(7):1126–31.PubMedCrossRef
377.
Baert F, Vande Casteele N, Tops S, et al. Prior response to infliximab and early serum drug concentrations predict effects of adalimumab in ulcerative colitis. Aliment Pharmacol Ther. 2014;40(11–12):1324–32.PubMedCrossRef
378.
Roblin X, Marotte H, Rinaudo M, et al. Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2014;12(1):80-84.e2.PubMedCrossRef
Metadaten
Titel
Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Inflammatory Bowel Disease
verfasst von
Luc J. J. Derijks
Dennis R. Wong
Daniel W. Hommes
Adriaan A. van Bodegraven
Publikationsdatum
06.03.2018
Verlag
Springer International Publishing
Erschienen in
Clinical Pharmacokinetics / Ausgabe 9/2018
Print ISSN: 0312-5963
Elektronische ISSN: 1179-1926
DOI
https://doi.org/10.1007/s40262-018-0639-4

Weitere Artikel der Ausgabe 9/2018

Clinical Pharmacokinetics 9/2018 Zur Ausgabe

Original Research Article

Pharmacokinetics of the B-Cell Lymphoma 2 (Bcl-2) Inhibitor Venetoclax in Female Subjects with Systemic Lupus Erythematosus

Original Research Article

Model-Based Therapeutic Drug Monitoring of Infliximab Using a Single Serum Trough Concentration

Letter to the Editor

Author’s Reply to Woillard et al.: “Population Pharmacokinetics of Mycophenolic Acid: an Update”

Original Research Article

Tacrolimus Concentration in Saliva of Kidney Transplant Recipients: Factors Influencing the Relationship with Whole Blood Concentrations

Original Research Article

Population Pharmacokinetic-Pharmacodynamic Modeling of Ropivacaine in Spinal Anesthesia

Systematic Review

Augmented Renal Clearance in Critically Ill Patients: A Systematic Review